A Novel Next-Generation Sequencing Assay for the Identification of BCR :: ABL1 Transcript Type and Accurate and Sensitive Detection of TKI-Resistant Mutations
The Journal of Applied Laboratory Medicine · 2024
DOI: 10.1093/jalm/jfae096 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, 2024. Verfasst von Zhenyu Yan und 6 weiteren Autor:innen. Beteiligte Einrichtung: ICON Laboratory Services, ICON plc, Cambridge, MA, United States. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Background
The clinical management of chronic myeloid leukemia (CML) patients requires the identification of the type of BCR::ABL1 transcript at diagnosis and the monitoring of its expression and potential tyrosine kinase inhibitor (TKI) resistance mutations during treatment. Detection of resistant mutation requires transcript type-specific amplification of BCR::ABL1 from RNA.
Methods
In this study, a custom RNA-based next-generation sequencing (NGS) assay (Dup-Seq BCR::ABL1) that enables (a) the identification of BCR::ABL1 transcript type and (b) the detection of resistance mutations from common and atypical BCR::ABL1 transcript types was developed and validated. The assay design covers BCR exon 1 to ABL1 exon 10 and employs duplicate PCR amplification for error correction. The custom data analysis pipeline enables breakpoint determination and overlapped mutation calling from duplicates, which minimizes the low-level mutation artifacts.
Results
This study demonstrates that this novel assay achieves high accuracy (positive percent agreement (PPA) for fusion: 98.5%; PPA and negative percent agreement (NPA) for mutation at 97.8% and 100.0%, respectively) and sensitivity (limit of detection (LOD) for mutation detection at 3% from 10 000 copies of BCR::ABL1 input).
Conclusions
The Dup-Seq BCR::ABL1 assay not only allows for the identification of BCR::ABL1 typical and atypical transcript types and accurate and sensitive detection of TKI-resistant mutations but also simplifies molecular testing work flow for the clinical management of CML patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- ICON Laboratory Services, ICON plc, Cambridge, MA, United States.
Zitieren
APA
Yan, Z., Shi, L., Li, W., Liu, W., Galderisi, C., Spittle, C., & Li, J. (2024). A Novel Next-Generation Sequencing Assay for the Identification of BCR :: ABL1 Transcript Type and Accurate and Sensitive Detection of TKI-Resistant Mutations. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfae096
Vancouver
Yan Z, Shi L, Li W, Liu W, Galderisi C, Spittle C, et al. A Novel Next-Generation Sequencing Assay for the Identification of BCR :: ABL1 Transcript Type and Accurate and Sensitive Detection of TKI-Resistant Mutations. The Journal of Applied Laboratory Medicine. 2024. doi:10.1093/jalm/jfae096
BibTeX
@article{Yan2024,
author = {Yan, Zhenyu and Shi, Lin and Li, Wei and Liu, Weihua and Galderisi, Chad and Spittle, Cynthia and Li, Jin},
title = {A Novel Next-Generation Sequencing Assay for the Identification of BCR :: ABL1 Transcript Type and Accurate and Sensitive Detection of TKI-Resistant Mutations},
journal = {The Journal of Applied Laboratory Medicine},
year = {2024},
doi = {10.1093/jalm/jfae096}
}
EUVIMED